Stay updated on Sacituzumab vs Chemo in HR+/HER2- Metastatic Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Sacituzumab vs Chemo in HR+/HER2- Metastatic Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Sacituzumab vs Chemo in HR+/HER2- Metastatic Breast Cancer Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    A banner announces NIH’s terminology transition from “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.
    Difference
    1%
    Check dated 2026-10-24T17:42:25.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov page remains a 403 Forbidden error page; its footer revision number changed from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-17T17:19:14.000Z thumbnail image
  3. Check
    14 days ago
    Change Detected
    Summary
    The site’s footer revision identifier advances from v3.7.0 to v3.7.1 on a study record page displaying a 403 error.
    Difference
    0.2%
    Check dated 2026-10-10T18:44:50.000Z thumbnail image
  4. Check
    35 days ago
    Change Detected
    Summary
    The study record page now shows a 403 Forbidden error, replacing the previous study details and links with an error message. This indicates the record is currently inaccessible and removes access to the study information.
    Difference
    18%
    Check dated 2026-09-19T19:30:25.000Z thumbnail image
  5. Check
    56 days ago
    Change Detected
    Summary
    NIH funding reference for 2018 was added to the funding information. A new publication citation by Sathe et al. on Sacituzumab Govitecan pharmacokinetics was added to the Publications/IPD section, and the revision tag was updated from v3.6.5 to v3.6.6.
    Difference
    0.1%
    Check dated 2026-08-29T20:10:41.000Z thumbnail image
  6. Check
    78 days ago
    Change Detected
    Summary
    The page shows Revision: v3.6.5 replacing v3.6.4. This indicates a minor update to the page’s revision, likely affecting internal documents or UI rather than the study content.
    Difference
    0.0%
    Check dated 2026-08-08T10:38:39.000Z thumbnail image

Stay in the know with updates to Sacituzumab vs Chemo in HR+/HER2- Metastatic Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Sacituzumab vs Chemo in HR+/HER2- Metastatic Breast Cancer Clinical Trial page.